CIBFX
Price
$69.11
Change
+$0.98 (+1.44%)
Updated
Apr 11 closing price
Net Assets
103.34B
LGMCX
Price
$22.18
Change
+$0.31 (+1.42%)
Updated
Apr 11 closing price
Net Assets
2.63B
Ad is loading...

CIBFX vs LGMCX

Header iconCIBFX vs LGMCX Comparison
Open Charts CIBFX vs LGMCXBanner chart's image
American Funds Capital Income Bldr F1
Price$69.11
Change+$0.98 (+1.44%)
VolumeN/A
Net Assets103.34B
Loomis Sayles Global Allocation C
Price$22.18
Change+$0.31 (+1.42%)
VolumeN/A
Net Assets2.63B
CIBFX vs LGMCX Comparison Chart
Loading...
View a ticker or compare two or three
VS
CIBFX vs. LGMCX commentary
Apr 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CIBFX is a Hold and LGMCX is a Buy.

Ad is loading...
FUNDAMENTALS
Fundamentals
CIBFX has more cash in the bank: 103B vs. LGMCX (2.63B). CIBFX pays higher dividends than LGMCX: CIBFX (3.09) vs LGMCX (0.31). CIBFX was incepted earlier than LGMCX: CIBFX (24 years) vs LGMCX (19 years). LGMCX (1.91) is less costly to investors than CIBFX (0.66). CIBFX has a lower initial minimum investment than LGMCX: CIBFX (250) vs LGMCX (2500). CIBFX annual gain was more profitable for investors over the last year : 6.60 vs. LGMCX (-5.82). CIBFX return over 5 years is better than : 41.11 vs. LGMCX (1.03).
CIBFXLGMCXCIBFX / LGMCX
Total Expense Ratio0.661.9135%
Annual Report Gross Expense Ratio0.661.9135%
Fund Existence24 years19 years-
Gain YTD0.828-5.447-15%
Front LoadN/AN/A-
Min. Initial Investment250250010%
Min. Initial Investment IRAN/AN/A-
Net Assets103B2.63B3,918%
Annual Yield % from dividends3.090.311,012%
Returns for 1 year6.60-5.82-113%
Returns for 3 years9.80-7.49-131%
Returns for 5 years41.111.033,981%
Returns for 10 years31.2412.92242%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FBTIX24.57N/A
N/A
Fidelity Advisor Biotechnology I
MRGJX45.83N/A
N/A
MFS Core Equity R4
INSAX18.95N/A
N/A
Catalyst Insider Buying A
EMECX9.59N/A
N/A
Ashmore Emerging Markets Equity C
GMAYX20.32N/A
N/A
GMO Small Cap Quality I